Showing results (51-60 of 196) with videos related to
Sort By:
Pageof 20
Journal of the American Statistical Association|February 12, 2019
A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment RegimesThomas A Murray, Ying Yuan, Peter F ThallJournal of the Royal Statistical Society. Series C, Applied Statistics|March 13, 2012
Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknownYing Yuan, Peter F Thall, Johannes E WolffStatistics in Medicine|May 19, 2016
Utility-based designs for randomized comparative trials with categorical outcomesThomas A Murray, Peter F Thall, Ying YuanJournal of the Royal Statistical Society. Series C, Applied Statistics|April 2, 2016
Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free SurvivalBrian P Hobbs, Peter F Thall, Steven H LinJournal of the Royal Statistical Society. Series C, Applied Statistics|March 4, 2017
Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal OutcomesPeter F Thall, Hoang Q Nguyen, Ralph G ZinnerPharmaceutical Statistics|July 6, 2017
Bayesian nonparametric statistics: A new toolkit for discovery in cancer researchPeter F Thall, Peter Mueller, Yanxun Xu, et al.Journal of the American Statistical Association|September 15, 2015
Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and ToxicityJuhee Lee, Peter F Thall, Yuan Ji, et al.Biostatistics (Oxford, England)|November 11, 2015
A decision-theoretic phase I-II design for ordinal outcomes in two cyclesJuhee Lee, Peter F Thall, Yuan Ji, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 18, 2011
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastasesPaul Mathew, Sijin Wen, Satoshi Morita, et al.Biometrics|March 22, 2008
Patient-specific dose finding based on bivariate outcomes and covariatesPeter F Thall, Hoang Q Nguyen, Elihu H EsteyPageof 20